Every material Form 8-K Solid Biosciences Inc. has filed with the SEC since March 11, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Solid Biosciences filed a prospectus supplement under its existing shelf registration to offer up to $200.0 million of common stock through a sales agreement with Jefferies LLC. The company said it had already sold about $85.0 million of stock under a prior supplement, which it will no longer use once this one is filed.
Up to $200.0 million of common stock may be sold under the Amended and Restated Sales Agreement dated March 13, 2024 with Jefferies LLC.
Prior prospectus supplement covered up to $85.0 million; about $85.0 million in gross proceeds had been raised under it and the Sales Agreement as of the filing date.
Offering is made under the Form S-3 shelf registration (File No. 333-287325), declared effective May 27, 2025.
Wilmer Cutler Pickering Hale and Dorr LLP issued a legal opinion on the shares (Exhibit 5.1).
Solid Biosciences disclosed that director Ilan Ganot resigned from its Class III board seat and was appointed to a Class I seat effective April 10, 2026, to balance board class membership. The move carries no change to his compensation, and the company plans to ask stockholders to ratify the appointment at its 2026 annual meeting.
Ganot resigned from Class III and was appointed to Class I, effective 4:00 p.m. Eastern Time on April 10, 2026.
Class I term expires at the 2028 Annual Meeting of Stockholders; he will not stand for election in 2027.
No changes to Ganot's compensation and no compensation due from his resignation or appointment.
Board Class III reduced to three directors and Class I increased to three directors.
Solid Biosciences released new interim clinical data from its Phase 1/2 INSPIRE DUCHENNE trial of SGT-003, a one-time gene therapy for pediatric Duchenne muscular dystrophy, using a February 23, 2026 data cutoff. The company said SGT-003 has been generally well tolerated in 40 participants dosed as of March 11, 2026, and reported biomarker changes at Day 90 and Day 360 in small subsets of participants. The data are interim and based on small numbers, and the company said it expects a Phase 3 IMPACT DUCHENNE trial to begin dosing in the first quarter of 2026.
40 participants dosed as of March 11, 2026; data cutoff February 23, 2026
Mean microdystrophin expression by western blot was 60% at Day 90 (n=19) and 91% at Day 360 (n=3)
Mean 44% reduction in eMHC-positive fibers at Day 90 (n=20); serum creatine kinase down 38% at Day 90 (n=24)
Company plans additional FDA meetings in the first half of 2026 and expects further updates in mid-2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Solid Biosciences Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →